Key Takeaways
Novo’s acquisition of Catalent produced some unusual public objections, but was ultimately cleared without any conditions from regulators.
Catalent offered customers assurances that it would continue to focus on their manufacturing needs after the merger, but that was not a provision of regulatory approval.
The Novo/Catalent deal may have been simpler for antitrust authorities to clear because it involved a vertical acquisition rather than a horizontal one.
Throughout 2024, the acquisition of Catalent, one of the world’s biggest CDMOs, by Novo Holdings, the holding company for the global pharmaceutical giant Novo Nordisk, prompted much
Nevertheless, to some surprise from commentators, the acquisition has now been completed and without any conditions attached
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?